Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial

Rodica Pop-Busui^1,2; Søren Rasmussen³; John E. Deanfield⁴; John B. Buse⁵; Nikolaus Marx⁶; Sharon L. Mulvagh⁷; Silvio E. Inzucchi⁸; Johannes F. E. Mann⁹; Scott S. Emerson¹⁰; Neil R. Poulter¹¹; Mads D. M. Engelmann³; G. Kees Hovingh³; Katrine Bayer Tanggaard³; Andreas L. Birkenfeld^12,13,14; Kim A. Connelly¹⁵; Martin Haluzik¹⁶; Matthew A. Cavender⁵; Monika Kellerer¹⁷; Pardeep S. Jhund¹⁸; Søren Gregersen^19,20; Olav Wendelboe Nielsen³; Carolyn S. P. Lam^21,22; Darren K. McGuire²³; on behalf of the SOUL Study Group